An ISO 9001 - 2008 certified company
Important Links
TRIAMCINOLONE
Product:
TRIAMCINOLONE
Formulary:
Generic Formulary
Category:
Endocrine System
Sub Group:
CORTICOSTEROIDS
International Brand Name:
Kenolog,Aristocort, Nasacort, Tri-Nasal, Treiderm,Azmacort, Trilone,Volon A, Tricorlone, Triensence
Dosages:
4 MG/10 MG/ML/40ML/ML
Unit of Packing:
Tablets
In treatment of:
Replacement therapy in Adrenal insufficiency
Adverse Effects:
1.Susceptibility to infection
2.Peptic ulcer
3.Haemorrhage
4.Glycosuria
5.Hyperglycaemia
6.Osteoporosis
7.Atrophy of adrenal cortex(on prolonged therapy)
8.Suppression of adrenocorticotropic hormone
9.Cushing`s syndrome
10.Inhibition of growth in children
11.Amenorrhoea
12.Behavioral disturbances
13.Thromboembolic disorders
14.Myopathy
15.Weakness
16.Lymphocytopenia
17.Muscle wasting
18.Gastrointestinal discomfort
19.Increased appetite
20.Delayed wound healing
21.Headache
22.Euphoria
23.Insomnia
24.Seizures
25.Heart failure
26.Arrhythmias
27.Posterior sub capsular cataract
28.Glaucoma
29.Sodium and fluid retention
30.Hypo kalaemia
31.Increased intracranial pressure
Contraiindication:
1.Hypersensitivity to the drug
2.Epilepsy
3.Peptic ulcer
4.Tuberculosis
5.Systemic fungal infections
6.Herpes simplex
7.Renal impairment
8.Not to be given intravenously
Special Precaution:
1.Avoid sudden discontinuation of the drug
2.Monitor vital parameters, therapeutic response and adjust the dosage
3.Use lower dosages as much as possible
4.Osteoporosis
5.Primary glaucoma
6.Primary psychosis and psychoneurosis
7.Recent myocardial infarction
8.Heart failure
9.Diabetes mellitus
10.Hypothyroidism
11.Cirrhosis
12.Stress
13.Sepsis
14.Hypertension
15.Myasthenia gravis
16.Hepatic impairment
17.Non specific Ulcerative colitis
18.Diverticulitis
19.Recent intestinal anastomosis
20.Seizures
21.Thromboembolic disorders
Interaction:
Barbiturates: Decreases efficacy of triamcinolone.
Oral contraceptives: May increase half life and concentration of triamcinolone.
Oestrogens: May decrease clearance of triamcinolone.
Rifampicin: Decreases efficacy.
Triamcinolone effects the action of the following:
Anticiholinesterases: Efficacy antagonised in myasthenia gravis.
Oral anticoagulants: Altered response.
Cyclosporine: Increased cyclosporine efficacy, toxicity may be enhanced.
Digitalis glycosides: Increased possibility of toxicity associated with hypokalaemia.
Isoniazid: Decreased serum levels of isoniazid.
Salicylates: Decreased serum levels of salicylates.
Diuretics: May cause increased hypokalaemia and increased hyperglycemia.
Non-depolarising muscle relaxants: Altered response.
Theophyllines: Altered response of either agent.
Lab Tests: Increases serum cholesterol levels. Increases urine glucose levels. Decreases Thyroid I uptake. Decreases T3 serum levels. Decreases serum potassium.
Servings:
Oral: 4 to 32mg/day as once daily or 2 to 4 divided doses depending up on the severity of the condition.
Children: 4 to 12mg/day
Adrenal insufficiency: 4 to 12mg/day as once daily or as divided doses depending up on the severity of the condition.
Children: 117mcg/kg/day as once daily or as divided doses.
Collagen diseases, Tuberculous meningitis: 30 to 48mg/day.
Respiratory diseases: 16 to 48mg/day as once daily or as divided doses depending up on the severity of the condition.
Malignancies: 16 to 100mg/day as once daily or as divided doses depending up on the severity of the condition.
Parenteral: 4 to 32mg/day as once daily or as divided doses
I.M.: 40 to 60mg as deep I.M. injection depending up on the severity of the condition.
In asthma and hey fever increases the dosage up to 100mg as required by the patient.
Intra-articular: 2.5mg to 15mg depending up on the severity of the condition.
Intradermal: 0.2 to 0.3ml
